Alnylam Pharmaceuticals, Inc. $ALNY Stock Holdings Lessened by Brown Advisory Inc.

Brown Advisory Inc. reduced its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 6.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 29,471 shares of the biopharmaceutical company’s stock after selling 1,914 shares during the quarter. Brown Advisory Inc.’s holdings in Alnylam Pharmaceuticals were worth $9,610,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company’s stock valued at $4,336,064,000 after buying an additional 240,534 shares during the period. T. Rowe Price Investment Management Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 0.8% during the first quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company’s stock worth $1,192,988,000 after acquiring an additional 33,696 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Alnylam Pharmaceuticals by 5.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company’s stock valued at $946,466,000 after purchasing an additional 185,783 shares during the last quarter. Geode Capital Management LLC grew its stake in Alnylam Pharmaceuticals by 3.3% in the second quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock valued at $779,857,000 after purchasing an additional 75,936 shares in the last quarter. Finally, Norges Bank acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter worth about $662,837,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Piper Sandler reissued an “overweight” rating and issued a $489.00 price target (up previously from $449.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, October 31st. Stifel Nicolaus lifted their target price on shares of Alnylam Pharmaceuticals from $441.00 to $495.00 and gave the company a “buy” rating in a research note on Monday, October 6th. Jefferies Financial Group dropped their price target on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating on the stock in a research note on Thursday, October 30th. Citigroup raised their price target on shares of Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. Finally, Wells Fargo & Company upped their price objective on shares of Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. Twenty-three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $482.17.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 12,128 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $452.18, for a total value of $5,484,039.04. Following the transaction, the executive vice president directly owned 21,264 shares of the company’s stock, valued at $9,615,155.52. The trade was a 36.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Yvonne Greenstreet sold 15,650 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $453.69, for a total value of $7,100,248.50. Following the completion of the sale, the chief executive officer directly owned 65,409 shares of the company’s stock, valued at $29,675,409.21. This represents a 19.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 78,328 shares of company stock valued at $35,705,793 in the last ninety days. Company insiders own 1.20% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $458.12 on Monday. The company has a market capitalization of $60.52 billion, a PE ratio of 1,908.83 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55. The company has a debt-to-equity ratio of 4.45, a current ratio of 2.54 and a quick ratio of 2.49. The company’s fifty day moving average price is $456.78 and its 200 day moving average price is $403.79.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.